Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...

Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...

Merck reports positive results from phase 3 trial of once-daily, oral, two-drug, single-tablet regimen of Doravirine/Islatravir in treatment-naïve adults with HIV-1 infection ...

The investigational oral therapy combines doravirine, a non-nucleoside reverse transcriptase inhibitor, with islatravir, a nucleoside reverse transcriptase translocation inhibitor, in a single tablet ...

Merck on Wednesday said the Phase 3 study of the once-daily, two-drug single-tablet regimen met the success criterion for its primary efficacy hypothesis, showing non-inferiority to the three-drug ...

Merck said on Wednesday that its experimental oral HIV treatment met the main goal of a late-stage trial. The company said ...

MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).

Merck (MRK) announced topline results from the pivotal double-blind Phase 3 trial of the investigational, once-daily, oral, two-drug, ...

Key goals of EHE include, from 2017 to the end of 2025, reducing new HIV infections and diagnoses by 75%, increasing viral suppression among PWH to 95%, and increasing good or better self-rated health ...

Investing.com - RBC Capital maintained its Sector Perform rating and $100.00 price target on Gilead Sciences (NASDAQ:GILD), a prominent player in the biotechnology industry with $28.9 billion in ...